Bulgaria joins the euro area amid smooth cash changeover and rising influence in ECB policymaking • Euro cash transition completed with 70% circulation by Jan 2026 • Bulgaria gains seat at ECB policy table, active in Eurosystem committees • Emphasizes scale benefits: financial integration, resilience, infrastructure innovation • Highlights need for domestic reforms: governance, public investment, fiscal sustainability • Growth expected to outpace euro area, with risks of overshoot; macroprudential measures in place Original Press Release: www.ecb.europa.eu//pre... #ECB #EuropeanCentralBank

Banks’ linkages with non-bank financial sector pose systemic vulnerabilities; concentrated in large euro area G-SIBs, risks may amplify under stress. • Key roles: liquidity, leverage, market-making • Risks linked to data gaps, limited EU and outside exposures visibility • Vulnerabilities could intensify in adverse conditions • Emphasis on improved data sharing and centralized access Original Press Release: www.ecb.europa.eu//pre... #ECB #EuropeanCentralBank

Europe must reduce dependencies in payments and digital finance to safeguard monetary sovereignty amid geopolitical shifts * Digital retail payments rely heavily on non-European solutions, risking resilience and control. * A digital euro is planned to ensure European payment sovereignty, interoperability, and reduce reliance on international schemes. * Tokenised central bank money will support secure, euro-denominated digital settlement, countering US dollar stablecoins. * Expanding links between European fast payment systems will enhance cross-border efficiency and reduce third-currency exposure. * Strengthening domestic funding for innovative firms aims to boost growth, retain talent, and improve policy transmission. * Addressing dependencies enhances resilience, competitiveness, and supports Europe’s strategic independence. Original Press Release: www.ecb.europa.eu//pre... #ECB #EuropeanCentralBank

FDA removes boxed warnings on 6 menopausal hormone therapies to improve risk clarity and support informed women’s choices. • Warnings on cardiovascular, breast cancer, and dementia risks eliminated after review • Includes systemic, topical, estrogen, progestogen, and combination therapies • Initiated in Nov 2025, with 29 companies submitting label updates • Aims to enhance accurate risk-benefit understanding for women and clinicians • Supports informed decision-making for menopause symptom management Original Press Release: www.fda.gov/news-event... #FDA #USFDA

FDA sets new acceptable intake limits for nitrosamine impurities in drugs, updates implementation timelines, and enhances testing guidance. • AI limits based on carcinogenic potency categorization and compound-specific data • Interim limits for certain nitrosamines, with phased implementation through 2026 • New analytical and safety testing methods recommended for confirmatory detection • Updated timelines for risk assessment, testing, and submission of mitigation strategies • Focus on controlling NDSRIs in drug manufacturing to mitigate carcinogenic risks Original Press Release: www.fda.gov/regulatory... #FDA #USFDA

FDA clarifies expanded access pathways for investigational drugs amid new statutory requirements • Webinar on regulatory framework, submission process, and reporting for expanded access programs • Covers three categories: individual patient, intermediate-size, treatment INDs • Focus on compliance, resource tools, and recent legislative updates (21st Century Cures Act, FDARA) • Targeted at sponsors, clinicians, IRBs, patient advocates, and regulators • CE credits available for industry and healthcare professionals Original Press Release: www.fda.gov/drugs/news... #FDA #USFDA

Allergy alert: Undeclared milk and soy in Junebar snack bars prompts recall • Affected products: Chocolate Cherry, Peanut Butter Chocolate Chip Junebars, batch L1300/L1301 • Distributed in NY, January 2026, via retailers and website orders • Cause: Sourcing oversight led to inclusion of milk/soy-containing chocolate chips • Risk: Severe allergic reactions in sensitive individuals • Consumer action: Return for full refund, contact 315-226-3339 or contact@junebars.com Original Press Release: www.fda.gov/safety/rec... #FDA #USFDA

Recall of Wellsley Farms Atlantic Salmon at BJ’s due to Listeria risk • Lot 3896, sold Jan 31–Feb 7, 2026, in multiple states • Potential contamination with Listeria monocytogenes identified by FDA sampling • No illnesses reported; risk for pregnant women includes miscarriage, stillbirth • Product in 2-lb bags, UPC 888670025963, lot number on reverse • Company investigating contamination source, taking corrective steps • Consumers advised to contact 1-888-628-0730 for refunds and disposal guidance Original Press Release: www.fda.gov/safety/rec... #FDA #USFDA

FDA removes boxed warnings on 6 menopausal hormone therapies to improve risk clarity and support informed women’s choices. • Warnings on cardiovascular, breast cancer, and dementia risks eliminated after review • Includes systemic, topical, estrogen, progestogen, and combination therapies • Initiated in Nov 2025, with 29 companies submitting label updates • Aims to enhance accurate risk-benefit understanding for women with menopause symptoms • Supports informed decision-making amid low current HRT utilization Original Press Release: www.fda.gov/news-event... #FDA #USFDA

FDA collaborates with public-private consortia to bridge science gaps in drug development, advancing regulatory tools and innovation. - Engages with multiple stakeholders including academia, industry, and government - Facilitates development of biomarkers, imaging, genetic tests, and digital tools - Uses formal processes for staff participation via MAPP 4100.2 - Active in initiatives like AMP, BioCelerate, and the Critical Path Consortium - Focuses on accelerating medicines and improving regulatory science Original Press Release: www.fda.gov/drugs/scie... #FDA #USFDA

FDA completes key PDUFA VI deliverables on drug safety, data standards, and stakeholder engagement; highlights progress in regulatory modernization. • Sentinel system assessment published 9/30/2022 • Multiple public meetings on electronic data standards (2018-2022) • Final guidance on adaptive trial designs issued 11/29/2019 • Independent reviews on combination products and safety signals (2020-2023) • Patient-focused guidance and workshops advancing clinical trial methods • Updates on staffing, financial plans, and electronic submission metrics Original Press Release: www.fda.gov/industry/p... #FDA #USFDA

Menopausal hormone therapies update with new prescribing info for Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva • Updated labels include safety and efficacy data • Prometrium (progestogen), Divigel, Cenestin, Enjuvia (estrogens) • Estring (vaginal estrogen), Bijuva (estrogen + progestogen) • Affects prescribing practices and patient management Original Press Release: www.fda.gov/drugs/drug... #FDA #USFDA

FDA proposes removing cardiovascular, breast cancer, and probable dementia risks from menopausal hormone therapy Boxed Warnings to clarify benefit/risk profile. • Removes language on cardiovascular, breast cancer, probable dementia risks from Boxed Warning • Retains endometrial cancer warning for systemic estrogen-alone products • Adds guidance on initiating therapy for women under 60 or within 10 years of menopause • Incorporates WHI data for women aged 50-59 in labeling • Condenses safety info for local vaginal estrogen products • Updates prescribing info across all MHT formulations Original Press Release: www.fda.gov/drugs/drug... #FDA #USFDA

FDA approves first portable device delivering electrical fields for pancreatic cancer treatment - Optune Pax by Novocure uses tumor treating fields to disrupt cancer cell division - Approved via premarket approval pathway after clinical trial showing ~2-month survival benefit - Device worn with adhesive patches, enabling continuous, at-home therapy - Breakthrough Device designation granted in Dec 2024 to expedite access - Addresses urgent need amid 67,440 new diagnoses in 2025 Original Press Release: www.fda.gov/news-event... #FDA #USFDA

FDA enhances oversight of prescription stimulants amid rising use and overdose risks • Doubling of prescriptions from 2011-2022, especially in adults • New label updates and safety warnings for stimulant medications • Funding research on stimulant use disorder treatments and adult ADHD management • Initiatives to promote safe prescribing, disposal, and online purchasing controls • Efforts to develop FDA-approved pharmacotherapies for stimulant use disorder Original Press Release: www.fda.gov/drugs/info... #FDA #USFDA

FDA finalizes guidance on antimicrobial use in food animals amid declining sales and increased surveillance efforts * Updates include defining durations of use for antibiotics in food animals. * 2.8 million resistant infections annually in US, over 35,000 deaths. * New antimicrobial susceptibility testing devices approved, including rapid diagnostics. * 2023 antimicrobial sales in food animals down 2% from 2022, 37% since 2015 peak. * Public comment period open for NARMS strategic plan through March 2025. * Ongoing collaborations with CDC, USDA, and international partners to combat AMR. Original Press Release: www.fda.gov/emergency-... #FDA #USFDA

FDA extends EUAs for COVID-19 treatments including Pemgarda, Gohibic, Kineret, Lagevrio, Paxlovid, and Olumiant amid PHE expiration; existing authorizations remain in effect. • Pemgarda EUA reissued with amendments through September 2025 • Gohibic authorized for hospitalized adults within 48 hours of ventilation • Kineret approved for at-risk adults with COVID-19 pneumonia • Lagevrio authorized for high-risk adults with mild-to-moderate COVID-19 • Paxlovid treatment expanded to pediatric patients, now also approved for adults • Olumiant authorized for pediatric COVID-19 in severe cases • PHE ending on May 11, 2023, but EUAs continue if criteria met Original Press Release: www.fda.gov/drugs/emer... #FDA #USFDA

President Trump highlights renewed focus on clean coal industry during recent remarks * Emphasizes technological advancements in coal cleaning * Promises support for coal industry jobs and infrastructure * Calls for policies balancing energy needs and environmental concerns * Reaffirms commitment to "beautiful, clean coal" as a national resource www.whitehouse.gov/art... #WhiteHouse #Articles

President Lincoln's birthday observed on February 12, 2026, with official commemorations and educational events nationwide. * Presidential proclamation issued recognizing Lincoln's legacy * Schools and institutions hold special programs * Focus on civil rights and national unity themes * Commemorations include wreath-laying ceremonies * Reflects ongoing emphasis on Lincoln's historical significance www.whitehouse.gov/bri... #WhiteHouse #BriefingsStatements

First Lady facilitates reunification of Russian and Ukrainian children * Coordinates with international agencies for child repatriation * Focuses on humanitarian and diplomatic efforts * Emphasizes importance of family reunification in conflict zones * Details ongoing cooperation with Russian and Ukrainian authorities * Aims to expedite process amid ongoing tensions www.whitehouse.gov/bri... #WhiteHouse #BriefingsStatements

Former Regions Bank employee barred for misappropriating customer funds • Consent prohibition order issued against Nicole M. Ramsey • Alleged misappropriation of customer funds at Birmingham branch • Enforcement action signals increased scrutiny on bank compliance • No monetary penalties announced; focus on misconduct prevention Original Press Release: www.federalreserve.gov... #FederalReserve #EnforcementActions

Government of India Securities Conversion/Switch Operation Conversion/Switch of Government of India Dated Securities – February 12, 2026: The Government of India conducted conversion/switch operations with the Reserve Bank on February 12, 2026, involving buyback of securities maturing in FY 2026-27 and issuance of new securities based on FBIL prices. These operations aim to smoothen the government's liability profile and support market development. Original Press Release: www.rbi.org.in/scripts... #RBI #CentralBank #India

Premature Redemption of Sovereign Gold Bond 2019-20 Series III Premature redemption – February 14, 2026: The Reserve Bank of India announced the premature redemption of the Sovereign Gold Bond (SGB) 2019-20 Series III, with a redemption date of February 13, 2026, due to a holiday on February 14. The redemption price is set at ₹15,641 per unit, based on the simple average gold price of ₹999 purity over the three preceding business days, as published by IBJA. Original Press Release: www.rbi.org.in/scripts... #RBI #CentralBank #India

Monetary Penalty on The Berhampur Co-operative Urban Bank Limited, Odisha – February 11, 2026: The RBI imposed a ₹2 lakh monetary penalty on The Berhampur Co-operative Urban Bank Limited, Odisha, for non-compliance with exposure norms and restrictions. The penalty followed a statutory inspection and supervisory findings of breaches in prudential inter-bank exposure limits. The action was based on regulatory deficiencies and does not comment on the validity of the bank's transactions. Original Press Release: www.rbi.org.in/scripts... #RBI #CentralBank #India

Draft Amendment Directions on Conduct in Loan Recovery and Engagement of Recovery Agents Announcement – February 6, 2026: The RBI has issued draft Amendment Directions to all regulated entities, including banks and financial institutions, to enhance conduct standards in loan recovery processes and engagement of recovery agents. These directions cover fair treatment of borrowers, conduct of recovery agents, due diligence, and training, with a public consultation open until March 6, 2026. The amendments aim to strengthen responsible business conduct across the financial sector. Original Press Release: www.rbi.org.in/scripts... #RBI #CentralBank #India

Monetary Penalty on Ganganagar Kendriya Sahkari Bank Limited – February 09, 2026: The RBI imposed a monetary penalty of ₹3 lakh on The Ganganagar Kendriya Sahkari Bank Limited, Rajasthan, for non-compliance with KYC directions. The penalty was based on supervisory findings and a statutory inspection conducted by NABARD, following deficiencies in regulatory compliance. The action does not comment on the validity of any transactions and is without prejudice to further actions. Original Press Release: www.rbi.org.in/scripts... #RBI #CentralBank #India

Digital Payments Index for September 2025 RBI – September 2025: The Reserve Bank of India announced the September 2025 Digital Payments Index (RBI-DPI) at 516.76, up from 493.22 in March 2025, indicating increased digitisation in payments driven by growth in Payment Performance and Payment Enablers. Original Press Release: www.rbi.org.in/scripts... #RBI #CentralBank #India

Seagate Technology Holdings (STX) announces $600M private exchange offer of 3.50% Senior Notes due 2028 for cash and new shares, closing around Feb 17, 2026 - Exchange involves $599.2M cash plus newly issued ordinary shares determined by Feb 12, 2026 market prices - Transaction reduces outstanding debt by $600M and increases share count via private placement - Targeted to select noteholders, exempt from Securities Act registration, signed off by CFO Gianluca Romano #Form8K #Debt #EquityIssuance Full summary: www.perivis.com/note/6... $STX.US

American Electric Power (AEP) doubles signed load growth agreements to 56 GW by 2030, driving a $5B–$8B expansion to its $72B capital plan - Load growth in Texas jumps from 13 GW to 36 GW, backed by signed agreements with hyperscalers and data centers - Secured $2.65B in fuel cell commitments and 10+ GW of gas turbine capacity for new generation projects - Reaffirmed 2026 operating earnings guidance of $6.15–$6.45 per share and 7–9% long-term growth target #Form8K #InvestorUpdate #CorporateUpdate Full summary: www.perivis.com/note/2... $AEP.US

Howmet Aerospace (HWM) reports Q4 revenue of $2.2B, up 15% YoY, with full-year 2025 revenue rising 11% to $8.3B and net income increasing 25% to $1.5B. - Full-year adjusted EBITDA grew 26% to $2.4B with margin expansion of 350 basis points - Generated $1.9B cash from operations and returned $700M to shareholders via buybacks in 2025 - Reduced debt by $265M and projects 10% revenue growth with improved profitability in 2026 #Form8K #EarningsUpdate #InvestorUpdate Full summary: www.perivis.com/note/1... $HWM.US